Affiliation:
1. 1SingHealth Duke-NUS Institute of Biodiversity Medicine, Singapore.
2. 2Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore.
Abstract
Summary:
Accessibility to standard of care remains a challenge to patients in low- and middle-income countries (LMIC), hampering efforts to alleviate the burden of cancer and to improve overall health outcomes. In response to this pressing global health care issue, we propose here a new strategy to create affordable, easily accessible, and effective therapeutic solutions to address this inequity in cancer treatment: the use of science-based biodiversity medicine as an alternative to modern drug therapy, in which we will leverage and combine high-throughput omics technologies with artificial intelligence, to study local biodiversity, their potential anticancer properties, and short- and long-term clinical response and outcomes.
Publisher
American Association for Cancer Research (AACR)
Reference15 articles.
1. Two centuries of biodiversity discovery and loss in Singapore;Chisholm;Proc Natl Acad Sci U S A,2023
2. Conservation and sustainable use of medicinal plants: problems, progress, and prospects;Chen;Chin Med,2016
3. A comparison of cultivation and wild collection of medicinal and aromatic plants under sustainability aspects;Schippmann;Medicinal and aromatic plants: agricultural, commercial, ecological, legal, pharmacological and social aspects: Wageningen International Nucleus for Strategic Expertise,2006
4. Overview of major classes of plant-derived anticancer drugs;Amin;Int J Biomed Sci,2009
5. Combination of phytochemicals as adjuvants for cancer therapy;Ho;Recent Pat Anticancer Drug Discov,2014